Gut feelings: A randomised, triple-blind, placebo-controlled trial of probiotics for depressive symptoms

Chahwan, Bahia; Kwan, Sophia; Isik, Ashling; Hemert, Saskia van; Burke, Catherine; Roberts, Lynette

doi:10.1016/j.jad.2019.04.097

Cited by 178 publications

(239 citation statements)

References 87 publications

Supporting

Mentioning

166

Contrasting

Unclassified

Order By: Relevance

“…The increase of Bacteroidaceae in the patients with depression and anxiety is consistent with a previous study that mice monocolonized with Bacteroides fragilis, which could also produce GABA [20], display de cits in serum serotonin [19]. Ruminococcus could predict serum serotonin and cortisol levels [30], and is signi cantly associated with a depression indicator [31] and IBD [32] and gut in ammation [33]. Lachnospiraceae and Ruminococcaceae, which accounted for 42.62% of the identi ed gut microbiota, could produce butyric acid, a subtype of short-chain fatty acids (SCFAs).…”

Section: Discussionsupporting

confidence: 90%

Crosstalk of multi-omics reveals specific characteristics in active ulcerative colitis patients with depression and anxiety

Yuan¹,

Chen²,

Duan³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background:Ulcerative colitis (UC) patients have a high incidence of mental disorders. The microbiota-gut-brain axis dysfunction is considered as one important pathogenesis of mental diseases. At present, little is known about how gut microbiota interact with the host in UC patients with depression and anxiety.Results: This prospective observational study enrolled 240 Chinese patients in two cohorts: the discovery cohort, including 69 active UC patients, 49 non-inflammatory bowel disease (IBD) depression and anxiety patients, and 62 healthy people, and the replication cohort of 60 active UC patients. About half of active UC patients showed symptoms of depression or anxiety. Through 16s rRNA sequencing, it was found that these UC patients accompanied with depression and anxiety had lower fecal microbial abundance with more Sellimonas , Eubacterium ventriosum group , Enterococcus , and Peptoclostridium , but less Prevotella_9 , Erysipelotrichaceae UCG_003 , Collinsella , and Dorea , compared with non-depressed/ anxious UC patients. Serum metabolome and proteome analysed using liquid chromatography/ mass spectrometry showed significantly increased glycochenodeoxycholate, stearoyllysophosphatidylcholine, and glyceryl stearates, while decreased 2'-deoxy-D-ribose and a set of immunoglobulin protein in the serum of UC patients with depression and anxiety. Through integration of multiple statistical analyses and multi-omics correlation analyses, we revealed a highly connected and comprehensive network, centring on Prevotella_9 and 1-stearoyl-sn-glycerol, composed of these bacteria, metabolites and proteins associated with UC-specific depression and anxiety.Conclusion: This study has identified a highly connected multi-omics network, composed of a set of gut microbiota, serum metabolites and proteins, specifically related to depression and anxiety in active UC. This network might influence host's mental state through mediating the effect of gut inflammation on synapse pruning in the central nervous system.

show abstract

Section: Discussionsupporting

confidence: 90%

Crosstalk of multi-omics reveals specific characteristics in active ulcerative colitis patients with depression and anxiety

Yuan¹,

Chen²,

Duan³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Probiotic bacteria may exert healthpromoting effects through various mechanisms that may be strainspecific (e.g., lactic acid bacteria) or widespread across a diversity of strains, including normalization of perturbed microbiota, inhibition of potential pathogens, production of useful metabolites or enzymes, and immunomodulation (Hill et al, 2014). Trials of probiotics have reported to improve symptoms of depression and psychological distress in patients with major depression (Akkasheh et al, 2016;Chahwan et al, 2019), multiple sclerosis (Kouchaki et al, 2017), chronic fatigue syndrome (Rao et al, 2009), and irritable bowel syndrome (Pinto-Sanchez et al, 2017). However, the findings are far from conclusive and there is very limited evidence for the efficacy of probiotic or prebiotic interventions on changing microbial composition in SMI (Okubo et al, 2019).…”

Section: Discussionmentioning

confidence: 99%

Gut microbiome in serious mental illnesses: A systematic review and critical evaluation

Nguyen

Hathaway

Kościółek

et al. 2021

Schizophrenia Research

View full text Add to dashboard Cite

Schizophrenia and bipolar disorder (BD) are associated with debilitating psychiatric and cognitive dysfunction, worse health outcomes, and shorter life expectancies. The pathophysiological understanding of and therapeutic resources for these neuropsychiatric disorders are still limited. Humans harbor over 1000 unique bacterial species in our gut, which have been linked to both physical and mental/cognitive health. The gut microbiome is a novel and promising avenue to understand the attributes of psychiatric diseases and, potentially, to modify them. Building upon our previous work, this systematic review evaluates the most recent evidence of the gut microbiome in clinical populations with serious mental illness (SMI). Sixteen articles that met our selection criteria were reviewed, including cross-sectional cohort studies and longitudinal treatment trials. All studies reported alterations in the gut microbiome of patients with SMI compared to non-psychiatric comparison subjects (NCs), and beta-diversity was consistently reported to be different between schizophrenia and NCs. Ruminococcaceae and Faecalibacterium were relatively decreased in BD, and abundance of Ruminococcaceae was reported across several investigations of SMI to be associated with better clinical characteristics. Lactic acid bacteria were relatively more abundant in SMI and associated with worse clinical outcomes. There was very limited evidence for the efficacy of probiotic or prebiotic interventions in SMI. As microbiome research in psychiatry is still nascent, the extant literature has several limitations. We critically evaluate the current data, including experimental approaches. There is a need for more unified methodological standards in order to arrive at robust biological understanding of microbial contributions to SMI.

show abstract

“…The selection process eventually yielded 23 studies to be included in the review process. (Akkasheh et al, 2016;Begtrup, De Muckadell, Kjeldsen, Christensen, & Jarbol, 2013;Benton, Williams, & Brown, 2007;Chahwan et al, 2019;Feher et al, 2014;Guyonnet et al, 2007;Herranen et al, 2003;Hilimire, DeVylder, & Forestell, 2015;Kato-Kataoka et al, 2016;Lorenzo-Zúñiga et al, 2014;Lyra et al, 2016;Malaguarnera et al, 2012;Marcos et al, 2005;Messaoudi et al, 2011;Östlund-Lagerström et al, 2016;Pinto-Sanchez et al, 2017;Rao et al, 2009;Romijn, Rucklidge, Kuijer, & Frampton, 2017;Shinkai et al, 2013;Steenbergen, Sellaro, van Hemert, Bosch, & Colzato, 2015;Stevenson, Blaauw, Fredericks, Visser, & Roux, 2014;Tillisch et al, 2013;Vaghef-Mehrabany et al, 2014).…”

Section: Re Sultsmentioning

confidence: 99%

“…The studies were published in several countries all over the world; however, they were mostly from the United States (N = 4) (17.4%). (Hilimire et al, 2015;Messaoudi et al, 2011;Rao et al, 2009;Tillisch et al, 2013;3) Concerning the period of publication, 11 studies (47.8%) were published between 2011 and 2015 (Akkasheh et al, 2016;Begtrup et al, 2013;Feher et al, 2014;Hilimire et al, 2015;Lorenzo-Zúñiga et al, 2014;Malaguarnera et al, 2012;Shinkai et al, 2013;Steenbergen et al, 2015;Stevenson et al, 2014;Tillisch et al, 2013;Vaghef-Mehrabany et al, 2014), 6 in the 2016-2019 period (Chahwan et al, 2019;Kato-Kataoka et al, 2016;Lyra et al, 2016;Östlund-Lagerström et al, 2016;Pinto-Sanchez et al, 2017;Romijn et al, 2017), 4 between 2006 and 2010 (Benton et al, 2007;Guyonnet et al, 2007;Messaoudi et al, 2011;Rao et al, 2009), and 2 before 2005. (Herranen et al, 2003;Marcos et al, 2005).…”

Section: Ta B L E 1 (Continued)mentioning

confidence: 99%

“…Seven studies (30.4%) were performed in a university setting (Chahwan et al, 2019;Kato-Kataoka et al, 2016;Lorenzo-Zúñiga et al, 2014;Östlund-Lagerström et al, 2016;Rao et al, 2009;Romijn et al, 2017;Shinkai et al, 2013), 5 (21.7%) in a hospital setting (Akkasheh et al, 2016;Herranen et al, 2003;Pinto-Sanchez et al, 2017;Tillisch et al, 2013;Vaghef-Mehrabany et al, 2014), and 4 (17.4%) in a medical office. (Begtrup et al, 2013;Chahwan et al, 2019;Feher et al, 2014;Marcos et al, 2005).…”

Section: Ta B L E 1 (Continued)mentioning

confidence: 99%

See 1 more Smart Citation

“Gut–brain axis”: Review of the role of the probiotics in anxiety and depressive disorders

et al. 2020

View full text Add to dashboard Cite

show abstract

Gut feelings: A randomised, triple-blind, placebo-controlled trial of probiotics for depressive symptoms

Cited by 178 publications

References 87 publications

Crosstalk of multi-omics reveals specific characteristics in active ulcerative colitis patients with depression and anxiety

Crosstalk of multi-omics reveals specific characteristics in active ulcerative colitis patients with depression and anxiety

Gut microbiome in serious mental illnesses: A systematic review and critical evaluation

“Gut–brain axis”: Review of the role of the probiotics in anxiety and depressive disorders

Contact Info

Product

Resources

About